Next-Generation Breast Cancer Diagnostic and Screening Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Next-Generation Breast Cancer Diagnostic and Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Others), By Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others), By Cancer Sub-Type (Luminal A, Luminal B, Triple Negative/Basal Like, Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched), By Offering (Products, Services), By End User (Hospitals and Clinics, Diagnostic Centers and Reference Labs, Academic and Research Institutes), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Next-Generation Breast Cancer Diagnostic and Screening Market is poised for substantial growth, projected to increase from USD 4.81 Billion in 2025 to USD 8.84 Billion by 2031, at a CAGR of 10.68%. This market includes advanced solutions like genomic profiling assays, liquid biopsy platforms, and AI-enhanced imaging systems, all designed to offer superior precision in detecting malignancies compared to traditional methods. Market expansion is primarily fueled by the rising global prevalence of breast cancer and a significant shift towards personalized medicine, which demands molecular-level tumor analysis for effective treatment strategies. For instance, the American Cancer Society anticipated approximately 316,950 women in the United States would be diagnosed with invasive breast cancer in 2025, highlighting the critical demand for these precise diagnostic capabilities.
Market Driver
A primary market driver is the integration of Artificial Intelligence (AI) in diagnostic imaging, which fundamentally enhances screening protocols by improving sensitivity and optimizing radiologist workflows. AI algorithms effectively identify subtle malignancies and mitigate false negatives in dense breast tissue, thereby significantly boosting diagnostic accuracy; a real-world study showed AI-supported screening increased breast cancer detection rates by 17.6%, achieving 6.7 detections per 1,000 women. Simultaneously, the increasing adoption of liquid biopsy and non-invasive diagnostics is transforming personalized medicine and treatment monitoring. These genomic tools enable early detection of circulating tumor DNA, allowing clinicians to dynamically tailor therapies and detect recurrence sooner than traditional imaging, proving vital as global breast cancer cases are projected to rise to 3.2 million annually by 2050.
Market Challenge
The high implementation costs associated with advanced technologies represent a significant challenge to the growth of the Global Next-Generation Breast Cancer Diagnostic and Screening Market. Integrating genomic profiling assays and AI-driven imaging systems demands substantial capital investment and specialized infrastructure, creating a financial barrier that many healthcare facilities, particularly in price-sensitive regions with stretched budgets, find difficult to overcome. Furthermore, existing reimbursement frameworks often inadequately cover the premium pricing of these innovative solutions, compelling providers to opt for less expensive, traditional methods despite the potential for enhanced detection. This economic strain extends to national health systems, where the substantial financial burden of breast cancer, projected to cost the UK economy between £3.2 billion and £3.5 billion annually in 2025, often prioritizes strict cost-containment measures over the adoption of premium diagnostic technologies, consequently limiting market scaling and widespread implementation.
Market Trends
The implementation of Automated Breast Ultrasound (ABUS) for screening dense breast tissue is becoming a key diagnostic standard, effectively addressing the limitations of conventional mammography, which often struggles with such tissue density. This volumetric 3D ultrasound technology ensures consistent, reproducible screening by de-linking image acquisition from operator skill, crucial for reducing false negatives and detecting interval cancers missed by X-ray systems; the Invenia ABUS Premium system, for example, detected 35.7% more cancers when used with mammography. Concurrently, the rising utilization of Contrast-Enhanced Mammography (CEM) offers a highly sensitive and cost-effective alternative to Magnetic Resonance Imaging (MRI) for high-risk assessments and inconclusive diagnoses. CEM utilizes iodinated contrast agents to visualize tumor neovascularization, providing superior clarity for lesion detection without the considerable operational costs or accessibility constraints of MRI protocols, with clinical studies indicating it successfully depicted 90% of breast cancers compared to just 10% with low-energy mammograms.
Key Market Players
* Exact Sciences Corporation
* F. Hoffmann-La Roche Ltd.
* Abbott Laboratories, Inc.
* Thermo Fisher Scientific Inc.
* Hologic, Inc.
* Siemens Healthineers AG
* Danaher Corporation
* Becton, Dickinson and Company
* Agilent Technologies, Inc.
* Sysmex Corporation
Report Scope
In this report, the Global Next-Generation Breast Cancer Diagnostic and Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Next-Generation Breast Cancer Diagnostic and Screening Market, By Technology
* Real-Time PCR
* Immunohistochemistry (IHC)
* Next-Generation Sequencing (NGS)
* Fluorescence In-Situ Hybridization (FISH)
* Others
# Next-Generation Breast Cancer Diagnostic and Screening Market, By Biomarker
* BRCA1/2
* ER/PR Receptors
* HER-2
* Others
# Next-Generation Breast Cancer Diagnostic and Screening Market, By Cancer Sub-Type
* Luminal A
* Luminal B
* Triple Negative/Basal Like
* Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched
# Next-Generation Breast Cancer Diagnostic and Screening Market, By Offering
* Products
* Services
# Next-Generation Breast Cancer Diagnostic and Screening Market, By End User
* Hospitals and Clinics
* Diagnostic Centers and Reference Labs
* Academic & Research Institutes
# Next-Generation Breast Cancer Diagnostic and Screening Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Next-Generation Breast Cancer Diagnostic and Screening Market.
Available Customizations:
Global Next-Generation Breast Cancer Diagnostic and Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Others)
5.2.2. By Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others)
5.2.3. By Cancer Sub-Type (Luminal A, Luminal B, Triple Negative/Basal Like, Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched)
5.2.4. By Offering (Products, Services)
5.2.5. By End User (Hospitals and Clinics, Diagnostic Centers and Reference Labs, Academic & Research Institutes)
5.2.6. By Region
5.2.7. By Company (2025)
5.3. Market Map
6. North America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Biomarker
6.2.3. By Cancer Sub-Type
6.2.4. By Offering
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Biomarker
6.3.1.2.3. By Cancer Sub-Type
6.3.1.2.4. By Offering
6.3.1.2.5. By End User
6.3.2. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Biomarker
6.3.2.2.3. By Cancer Sub-Type
6.3.2.2.4. By Offering
6.3.2.2.5. By End User
6.3.3. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Biomarker
6.3.3.2.3. By Cancer Sub-Type
6.3.3.2.4. By Offering
6.3.3.2.5. By End User
7. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Biomarker
7.2.3. By Cancer Sub-Type
7.2.4. By Offering
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Biomarker
7.3.1.2.3. By Cancer Sub-Type
7.3.1.2.4. By Offering
7.3.1.2.5. By End User
7.3.2. France Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Biomarker
7.3.2.2.3. By Cancer Sub-Type
7.3.2.2.4. By Offering
7.3.2.2.5. By End User
7.3.3. United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Biomarker
7.3.3.2.3. By Cancer Sub-Type
7.3.3.2.4. By Offering
7.3.3.2.5. By End User
7.3.4. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Biomarker
7.3.4.2.3. By Cancer Sub-Type
7.3.4.2.4. By Offering
7.3.4.2.5. By End User
7.3.5. Spain Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Biomarker
7.3.5.2.3. By Cancer Sub-Type
7.3.5.2.4. By Offering
7.3.5.2.5. By End User
8. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Biomarker
8.2.3. By Cancer Sub-Type
8.2.4. By Offering
8.2.5. By End User
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Biomarker
8.3.1.2.3. By Cancer Sub-Type
8.3.1.2.4. By Offering
8.3.1.2.5. By End User
8.3.2. India Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Biomarker
8.3.2.2.3. By Cancer Sub-Type
8.3.2.2.4. By Offering
8.3.2.2.5. By End User
8.3.3. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Biomarker
8.3.3.2.3. By Cancer Sub-Type
8.3.3.2.4. By Offering
8.3.3.2.5. By End User
8.3.4. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Biomarker
8.3.4.2.3. By Cancer Sub-Type
8.3.4.2.4. By Offering
8.3.4.2.5. By End User
8.3.5. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Biomarker
8.3.5.2.3. By Cancer Sub-Type
8.3.5.2.4. By Offering
8.3.5.2.5. By End User
9. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Biomarker
9.2.3. By Cancer Sub-Type
9.2.4. By Offering
9.2.5. By End User
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Biomarker
9.3.1.2.3. By Cancer Sub-Type
9.3.1.2.4. By Offering
9.3.1.2.5. By End User
9.3.2. UAE Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Biomarker
9.3.2.2.3. By Cancer Sub-Type
9.3.2.2.4. By Offering
9.3.2.2.5. By End User
9.3.3. South Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Biomarker
9.3.3.2.3. By Cancer Sub-Type
9.3.3.2.4. By Offering
9.3.3.2.5. By End User
10. South America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Biomarker
10.2.3. By Cancer Sub-Type
10.2.4. By Offering
10.2.5. By End User
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Biomarker
10.3.1.2.3. By Cancer Sub-Type
10.3.1.2.4. By Offering
10.3.1.2.5. By End User
10.3.2. Colombia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Biomarker
10.3.2.2.3. By Cancer Sub-Type
10.3.2.2.4. By Offering
10.3.2.2.5. By End User
10.3.3. Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Biomarker
10.3.3.2.3. By Cancer Sub-Type
10.3.3.2.4. By Offering
10.3.3.2.5. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Next-Generation Breast Cancer Diagnostic and Screening Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Exact Sciences Corporation
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd.
15.3. Abbott Laboratories, Inc.
15.4. Thermo Fisher Scientific Inc.
15.5. Hologic, Inc.
15.6. Siemens Healthineers AG
15.7. Danaher Corporation
15.8. Becton, Dickinson and Company
15.9. Agilent Technologies, Inc.
15.10. Sysmex Corporation
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們